METTL3 and cancer: Pan-cancer analysis showed that METTL3 expression was up-regulated in a variety of cancers, and higher METTL3 expression levels were significantly associated with poorer overall survival in ACC, KICH and LIHC, and poorer DFS in ACC, CESC, HNSC, KICH and LIHC.